Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma

NCT01403415 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01403415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01403415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2011
Completion date
Not reported
Enrollment
13 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

childhood b acute lymphoblastic leukemia, childhood t acute lymphoblastic leukemia, mature t-cell and nk-cell non-hodgkin lymphoma, recurrent childhood acute lymphoblastic leukemia, recurrent childhood lymphoblastic lymphoma